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Objective To collate the clinical response and pathogen eradication rates for meropenem monotherapy with
in vitro susceptibility of the causative pathogens.
Methods Data were compiled from 17 randomized clinical studies that compared meropenem monotherapy
with standard treatment options, often combinations. A total of 4906 pathogens from lower respiratory tract,
intra-abdominal, obstetric/gynecological, skin/soft tissue, meningitis, or pediatric infections were assessed. Of
these, 3713 pathogens (1963 meropenem, 1750 comparators) were evaluable.
Results The overall rates of satisfactory clinical response (cure or improvement) and pathogen eradication
(eradication or presumed eradication) at the end of therapy were similar with meropenem (93% for both
responses) and the comparators (92%), as were the rates in each infection type. For each pathogen, the clinical
response and eradication rates with meropenem were similar across the minimum inhibitory concentration
(MIC) range of 0.25 to 4 mg/L. Overall, a satisfactory clinical response occurred in 93% (1580 of 1708) of
infections caused by nonfastidious pathogens with MICs 4 mg/L and in 84% (16 of 19) of those with an
MIC of 8 mg/L. Pathogen eradication rates were similar (93 and 79%, respectively). A similar profile was
observed for fastidious pathogens. The high rates of satisfactory clinical response and pathogen eradication
produced by meropenem in each type of infection were generally independent of the causative pathogen,
whether Gram-positive or -negative aerobe or anaerobe or when occurring as mono- or polymicrobial
infections.
Conclusions The attractive in vitro profile of meropenem translates into good clinical efficacy. The National
Committee for Clinical Laboratory Standards has now defined meropenem MIC breakpoints for nonfastidious
aerobes or anaerobes as 4 (susceptible), 8 (intermediate) and 16 mg/L (resistant), respectively. The
susceptibility breakpoint for Streptococcus spp. (excluding Streptococcus pneumoniae) is 0.5 mg/L and, since
meropenem is indicated for the treatment of meningitis, the susceptibility breakpoint for S. pneumoniae and
Haemophilus influenzae is 0.25 and 0.5 mg/L, respectively. Meropenem monotherapy is therefore a valid
option for the initial empirical treatment of a range of serious infections caused by single or multiple bacterial
pathogens.
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INTRODUCTION
Meropenem is a parenteral carbapenem antibacterial with
properties appropriate for empirical therapy [reviewed by 1–3].
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In most countries in which it is available, meropenem is licensed
for use in the treatment of a broad range of infections, including
lower respiratory tract, intra-abdominal, obstetric/gyneco-
logical, urinary tract, skin/skin structure, meningitis, and also in
cystic fibrosis and febrile neutropenia. This range of indications
reflects the exceptional in vitro antibacterial spectrum of mer-
openem, which encompasses most clinically relevant Gram-
positive and Gram-negative aerobes and anaerobes [4–7]. In
comparison with imipenem, the only other carbapenem avail-
able outside Japan, meropenem is slightly less potent in vitro
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against some Gram-positive aerobes. However, meropenem is
more potent than imipenem against Gram-negative aerobes
(including Enterobacteriaceae and Pseudomonas aeruginosa) and
nutritionally fastidious organisms.
The key to the unrivalled antibacterial spectra of the car-
bapenems can be attributed in part to their exceptional stability
to b-lactamases. This stability extends to almost all serine-based
b-lactamases, including derepressed Class I enzymes and the
mutant TEM/SHV extended-spectrum b-lactamases that are
capable of hydrolyzing third-generation cephalosporins and, to
some extent, the newer cephalosporins such as cefepime [8–11].
There are very infrequent reports describing Enterobacteriaceae
with serine b-lactamases that are capable of hydrolyzing car-
bapenems [12–15]. However, the susceptibility of carbapenems
to hydrolysis by b-lactamases is generally limited to the zinc-
dependent enzymes expressed by less common pathogens such
as Stenotrophomonas maltophilia and certain strains of Aeromonas
hydrophila and Bacteroides spp. [16,17]. The only other important
pathogens that are clinically resistant to meropenem are methi-
cillin-resistant staphylococci and Enterococcus faecium, which are
also resistant to all other b-lactams. Although the minimum
inhibitory concentrations (MICs) of meropenem for strains of
Streptococcus pneumoniae categorized as being penicillin-inter-
mediate or -resistant are poorer than for susceptible strains, they
remain low [5,6].
To be effective in the clinical setting, the in vitro properties
of any antimicrobial agent must be accompanied by a favorable
pharmacokinetic profile. For b-lactam antibacterials, the rate of
bacterial kill is determined by the amount of time that the drug
concentration remains above the MIC for the pathogen [18].
In healthy volunteers, single meropenem doses of 1 g produce
plasma concentrations that equal or exceed the MICs for almost
all target pathogens for 75% of the recommended 8-h dosing
interval [19]. However, data from animal models have shown
that it is not necessary for b-lactams to exceed the MIC for the
entire dosage interval for a maximal bactericidal effect to occur
[20]. Indeed, data suggest that carbapenems will be thera-
peutically effective if their concentration exceeds the MIC for
25–40% of the 8-h dosing interval, i.e. 2 to 3.2 h [21].
An extensive multinational clinical trial programme has
evaluated the clinical efficacy of meropenem. In this paper, the
clinical and pathogen eradication rates achieved after mer-
openem monotherapy in patients with a variety of infections are
compared with in vitro pathogen susceptibility data to determine
whether susceptibility data are predictive of clinical response.
METHODS
Clinical trial program
This analysis was derived from data from 17 randomized par-
allel-group trials that compared meropenem (0.5 to 2 g intra-
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venously, 8-hourly) with standard treatment options in
hospitalized patients with a variety of infections (Table 1). It
focuses on six principal types of infection: lower respiratory
tract (hospital- and community-acquired infections), intra-
abdominal, obstetric/gynecological, skin/skin structure, men-
ingitis and pediatric infections (including lower respiratory tract,
intra-abdominal, skin/soft tissue infections or presumed sep-
ticemia). Key exclusion criteria applied across all studies
included: pregnancy or lactation; neutropenia or cystic fibrosis;
hepatic impairment; central nervous system disease (with the
exception of meningitis in studies conducted specifically in this
patient population); severe underlying disease (patients likely to
complete 48 h treatment were excluded); inadequate dur-
ation of treatment with either meropenem or comparator; anti-
biotic treatment within 3 days of trial therapy (unless the
pathogen was not eradicated or resistant to the previous treat-
ment); and previous trial entry.
Satisfactory clinical response was defined as cure or improve-
ment, whereas satisfactory pathogen eradication included eradi-
cation and presumed eradication. The data have been presented
here by pathogen and not by patient; thus, a patient may be
counted more than once depending on the number of patho-
gens isolated per patient. Only pathogens susceptible to the
treatment antibiotic received by the patient were included in
this analysis. Many of the trials were initiated prior to the
publication of the Infectious Diseases Society of America guide-
lines [38]. Consequently, although the therapeutic outcome at
the end of therapy was assessed in all studies, relatively little
data were collected on outcome at follow-up examination.
Microbiological methods
The majority of participating centres used the National Com-
mittee for Clinical Laboratory Standards (NCCLS) methods
or SensititreTM trays (Radiometer, Westlake, OH, USA) to
determine the susceptibility of isolates to meropenem or the
comparator agent(s). Agreement between agar dilution and
microdilution tests (90%) was confirmed for both aerobes
and anaerobes [39–41].
At the commencement of the trial program, before NCCLS
values were available, the susceptibility of nonfastidious and
anaerobic species were tested over the MIC range 0.25 to
16 mg/L; in view of the submission of a license for meningitis
therapy, lower MIC breakpoints were used for nutritionally
fastidious species. The following meropenem MIC breakpoints
have now been approved by the NCCLS: for nonfastidious
aerobes and anaerobes these are 4, 8 and 16 mg/L, respec-
tively, for susceptible, intermediate and resistant; for
nutritionally fastidious species these are 0.25 mg/L for Neis-
seria meningitidis and Streptococcus pneumoniae and 0.5 mg/L for
Haemophilus influenzae and other Streptococcus spp. As a result
of the consistency between MIC breakpoints for meropenem
Drusano et al Meropenem—clinical response 187
Table 1 Details of clinical studies from which the current analysis was derived (all drugs were administered intravenously)
Infection [reference] Meropenem dosage Comparator drug and dosage
Lower respiratory tract
Community-acquired:
Mouton et al. [22]a 1 g/8 h Ceftazidime 2 g/8 h + amikacin 15 mg/kg/day
Romanelli et al. [23]; 0.5 g/8 h Ceftazidime 1 g/8 h
Berman et al. [24]
AstraZeneca, data on file 1 g/8 h Ceftazidime 2 g/8 h
Hospital-acquired:
Mouton et al. [22]a 1 g/8 h Ceftazidime 2 g/8 h + amikacin 15 mg/kg/day
Colardyn et al. [25]a,b 1 g/8 h Imipenem/cilastatin 1 g/8 h
Sieger et al. [26] 1 g/8 h Ceftazidime 2 g/8 h + tobramycin 1 mg/kg
AstraZeneca, data on file 1 g/8 h Ceftazidime 2 g/8 h
Intra-abdominal
Brismar et al. [27] 0.5 g/8 h Imipenem/cilastatin 0.5 g/8 h
Condon et al. [28] 1 g/8 h Clindamycin 0.9 g/8 h + tobramycin  5 mg/kg/day
Huizinga et al. [29] 1 g/8 h Cefotaxime 2 g/8 h + metronidazole 0.5 mg/8 h
Colardyn et al. [25]a,b; 1 g/8 h Imipenem/cilastatin 1 g/8 h
Geroulanos et al. [30];
Kanellakopoulou et al. [31]
Obstetric/gynecological
Hemsell et al. [32] 0.5 g/8 h Clindamycin 0.9 g/8 h + gentamicin 1.5 mg/kg/8 h
Skin/skin structure
Nichols et al. [33] 0.5 g/8 h Imipenem/cilastatin 0.5 g/6 h
Meningitis
Odio et al. [34] 40 mg/kg/8 h Cefotaxime 45 mg/kg/6 h
Klugman et al. [35]; 2 g/8 h (adults) or Cefotaxime 75–100 mg/kg/8 h or ceftriaxone
Schmutzhard et al. [36]; 40 mg/kg/8 h 80–100 mg/kg/day (adults and children)
AstraZeneca, data on file (children)
Paediatric
Snedden et al. [37] 20 mg/kg/8 h Cefotaxime 40 mg/kg/6 h + clindamycin 10 mg/kg/8 h + tobramycin 2–2.5 mg/kg/8 h
AstraZeneca, data on file 10–20 mg/kg/8 h Cefotaxime 100–150 mg/kg/day (maximum 2 g)
(maximum 1 g)
a Study included patients with various serious infections.
b Study conducted in severely ill patients.
recommended by most national advisory bodies, MIC data are
presented here in preference to zone sizes, which are subject to
a certain degree of international variability.
RESULTS
A total of over 2000 patients were recruited into the 17 com-
parative clinical trials analyzed here. From these patients 4906
pathogens were isolated; 2476 in the meropenem-treated pat-
ients and 2430 from the comparator group. Of these, 1963
pathogens in the meropenem group and 1750 pathogens from
patients treated with comparators were evaluable.
Overall, meropenem produced high rates of satisfactory
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clinical response (93%) and pathogen eradication (93%) at the
end of treatment similar to those observed with the established
comparator regimens (92% for both clinical response and patho-
gen eradication). Across infection types, response rates with
meropenem were generally consistent and similar to those with
the comparator regimens (Table 2).
Response by pathogen and minimum inhibitory concentration
Combined data from all infection types indicate that the overall
rates of satisfactory clinical response and pathogen eradication
produced by meropenem were similar across the most common
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Table 2 Overall rates of satisfactory clinical responsea and pathogen eradicationb at the end of therapy in patients treated with
meropenem or comparator agents
Meropenem Comparatorc
Clinical Pathogen Clinical Pathogen
Infection n response (%) eradication (%) n response (%) eradication (%)
Lower respiratory tract 212 90 88 214 81 87
Intra-abdominal 766 94 92 712 91 90
Obstetric/gynecological 601 90 95 503 95 97
Skin/skin structure 153 98 95 161 97 91
Meningitis 136 99 99 131 96 99
Pediatric 95 97 93 29 100 86
Total 1963 93 93 1750 92 92
a Cure or improvement.
b Eradication or presumed eradication.
c See Table 1 for details.
Gram-positive, Gram-negative and anaerobic pathogens iso-
lated (Tables 3 and 4).
Moreover, for each pathogen, the satisfactory clinical
response and pathogen eradication rates with meropenem were
similar across the MIC range tested, although the number of
isolates with higher MICs was limited. Considering the NCCLS
approved breakpoints for nonfastidious organisms, a satisfactory
clinical response was achieved with meropenem in 93% (1580
of 1708) of infections caused by pathogens with MICs
4 mg/L and 84% (16 of 19) of those with an MIC of 8 mg/L.
Respective pathogen eradication rates at these breakpoints were
93 and 79%. Satisfactory clinical response and pathogen eradi-
cation rates varied little between MICs of 0.25 to 4 mg/L
(89–93 and 82–94%, respectively).
When used to treat infections caused by the fastidious species
N. meningitidis and S. pneumoniae, meropenem produced sat-
isfactory clinical response and pathogen eradication rates of 97%
(111 of 114) and 99% (113 of 114), respectively, against isolates
with MICs at or below the breakpoint for susceptibility
(0.25 mg/L). Meropenem also had satisfactory clinical response
and pathogen eradication rates (both 98% [87/89]) against iso-
lates of H. influenzae with MICs 0.5 mg/L (the susceptibility
breakpoint for this pathogen).
The vast majority of pathogens that persisted (52 of 54) or
were associated with an unsuccessful clinical response (42 of
43) were fully susceptible (MIC  4 mg/L) to meropenem.
The three remaining isolates had MICs of 8 mg/L.
Response by pathogen and infection type
The high rates of satisfactory clinical response and pathogen
eradication produced by meropenem in each type of infection
were generally independent of causative pathogen (Table 5).
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 185–194
Predictably, S. pneumoniae was the single most common patho-
gen causing lower respiratory tract infections (20% of isolates).
Meropenem was bacteriologically effective in 100% of such
infections. Meropenem also produced good rates of success
against pathogens such as Enterobacteriaceae associated with
nosocomial pneumonia. Although response rates achieved with
meropenem were generally lower in respiratory tract infections
relative to those in other infections, a similar profile was
observed for the comparator regimens. In the meropenem
group, 22 of 212 pathogens were associated with clinical failure
compared to 41 of 214 in the comparator group; nine and 21
of these pathogens, respectively, were eradicated. Amongst the
persisting pathogens, 13 of 26 and eight of 27, respectively,
were P. aeruginosa mostly isolated from ventilated patients (10
and six). The pathogen eradication rate produced by mer-
openem against P. aeruginosa causing lower respiratory tract
infections (58%) was relatively low compared with the satis-
factory clinical response rate (84%); corresponding values for
comparator regimens were 69 and 65%, respectively.
Meropenem was highly effective against single or multiple
pathogens causing intra-abdominal infections, including the
predominant pathogens Escherichia coli and Bacteroides fragilis (22
and 9% of isolates, respectively). Although the number of iso-
lates was relatively small (n = 18), meropenem also dem-
onstrated good rates of satisfactory clinical response and
pathogen eradication against Enterococcus faecalis in patients with
intra-abdominal infections (83 and 78%, respectively). Cor-
responding satisfactory clinical response and pathogen eradi-
cation rates for comparator regimens against this pathogen (17
isolates) were 100 and 100%, respectively.
Meropenem achieved uniformly high response rates against
each of the pathogens causing meningitis. In this subgroup
of patients, the most commonly isolated pathogens were H.
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influenzae and N. meningitidis (48 and 31% of isolates, respec-
tively). For these pathogens, satisfactory clinical response rates
with meropenem approached 100%, whereas pathogen eradi-
cation rates were in the range 98–100%. Similarly high rates of
satisfactory clinical response and pathogen eradication (100%)
were observed for meropenem in patients with meningitis
caused by S. pneumoniae. Corresponding values for comparator
regimens against this pathogen were 87 and 100%, respectively.
DISCUSSION
The treatment of serious infections commonly involves the
initiation of antimicrobial therapy before the results of culture
and susceptibility tests are known. Suitable regimens for empiri-
cal therapy must therefore possess activity against the range of
likely causative pathogens, which partly depends on the type of
infection. Meropenem, which exhibits potent broad-spectrum
bactericidal activity, b-lactamase stability and good tissue pen-
etration, was evaluated in an extensive clinical trial programme.
When used as monotherapy, meropenem produced consistent
efficacy similar to that of standard treatment regimens, including
imipenem/cilastatin and combinations, in the treatment of a
variety of serious infections in adults and children [22–37; Astra-
Zeneca, data on file].
This paper is the first to collate clinical response and patho-
gen eradication rates after meropenem therapy with in vitro
susceptibility of the infecting pathogens. In general, the clinical
efficacy of meropenem was independent of the species of patho-
gen isolated, with similar results being achieved against Gram-
positive, Gram-negative and anaerobic species.
The data reported in this analysis support the NCCLS
approved meropenem MIC breakpoints for both fastidious and
nonfastidious organisms and anaerobes with high success rates
recorded. However, pathogen susceptibility (MIC  8 mg/L)
was an inclusion criterion in this analysis, and a range of doses
were administered. Taken together, this explains why a more
obvious MIC–related association with clinical outcomes was
not demonstrated. Thus, infections caused by bacteria with
MICs of 4 mg/L responded as well as those with MICs of
0.25 mg/L. Further, evaluation of the relatively small number
of unsuccessful treatment outcomes showed that most failures
occurred against isolates that were susceptible to meropenem.
For example, almost all isolates of Staphylococcus aureus, Entero-
bacteriaceae and B. fragilis against which meropenem was
unsuccessful had MICs of 0.25 mg/L. Since pharmaco-
dynamic data for meropenem would suggest a favourable clini-
cal response for these patients, other ‘patient’ factors with an
adverse effect on prognosis, such as severe underlying disease,
may have been responsible for treatment failure in these pati-
ents.
Patients in this analysis were treated with 0.5 to 2 g of
meropenem at an interval of 8 h, most often with 1 g. As these
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dose levels were defined by the individual protocols, they were
used irrespective of the organism, assuming susceptibility.
Given that the driver for the antibacterial activity of meropenem
is time above MIC and that only 25–40% of the interdosing
interval is required to be above MIC, there is the opportunity
to review the unit dose or the dose-interval. Using the above
parameters, it is predicted that infections caused by bacteria with
MICs of 0.25 mg/L would respond to 0.5 g of meropenem
administered at 8- to 12-h intervals and that bacteria with MICs
of 0.5 to 1 mg/L would respond to 0.5 g given 8-hourly.
Overall, meropenem displayed good clinical and bac-
teriological efficacy regardless of the type of infection.
However, although meropenem achieved a pathogen eradi-
cation rate of 88% in lower respiratory tract infections, this was
generally lower than that observed for other types of infection.
This can probably be explained by the lower eradication rates
observed against S. aureus and P. aeruginosa isolates (78 and
58%, respectively). Although these findings may have been
unexpected in view of the good antistaphylococcal and anti-
pseudomonal activity of meropenem observed in vitro [5] they
are consistent with clinical experience. Eller et al. [42] have
reported that less than ideal eradication rates can be expected
in patients who have underlying disease, are ventilated, have a
significant bacterial challenge and deteriorating lung function.
In the present analysis, all of the clinical and eradication failures
for P. aeruginosa infections occurred against isolates with MICs
of 4 mg/L, with over of half of the persistors having MICs
of 0.25 mg/L. This indicates that persistence of infection
was not related to the development of resistance. Also, since
resistance does not appear to emerge before at least 3 days
of meropenem treatment, initial empirical monotherapy with
meropenem is feasible until culture and susceptibility data are
available [25].
A similar profile was obtained for comparator regimens in
patients with lower respiratory tract infection, i.e. the overall
pathogen eradication rate was lower compared with other types
of infection, and a correspondingly lower pathogen eradication
rate against S. aureus and P. aeruginosa was observed (95 and
69%, respectively). This was paralleled by a low rate of clinical
success for comparator agents in the treatment of lower res-
piratory tract infections caused by these pathogens (80 and
65%, respectively). Indeed, the satisfactory clinical response
rate against P. aeruginosa was notably lower than that with
meropenem (84%). Taken together, these findings support the
view that other ‘patient’ factors might have been implicated in
treatment failure, and closer inspection of the individual studies
upon which the present analysis was derived may be useful.
The studies by Sieger et al. [26] and Berman et al. [24], in
hospital- and community-acquired lower respiratory tract
infections, respectively, showed good pathogen eradication
rates with meropenem against P. aeruginosa, with 80–100% of
pathogens being eradicated. However, lower eradication rates
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against this pathogen were observed by Mouton et al. [22] and
Colardyn et al. [25]. The authors of the former study noted that
most patients in whom P. aeruginosa persisted were receiving
ventilatory support and that since this organism can colonize
ventilator tubing, it is a recognized potential source of re-
infection in such situations. Colardyn et al. [25] acknowledged
the problems of treating pseudomonal lower respiratory tract
infections and pointed out that, in view of the good tolerability
profile of meropenem, it is theoretically possible to escalate the
dosage to 2 g 8-hourly when treating such difficult-to-treat
infections.
Meropenem monotherapy achieved high rates of satisfactory
clinical response and pathogen eradication in patients with
intra-abdominal infections. Traditionally, combination therapy
with two or three agents has been required to ensure sufficiently
broad-spectrum antibacterial coverage against these infections.
The adoption of monotherapy offers several potential advan-
tages, including convenience and better tolerability. Notable
findings from the present analysis are the excellent results
obtained with meropenem against Enterococcus faecalis, a com-
mon pathogen among patients with intra-abdominal and obste-
tric/gynecological infections. Compared with imipenem,
meropenem is slightly less potent against this organism in vitro
[5]. Nevertheless, meropenem achieved satisfactory clinical
response and pathogen eradication rates of 83 and 78%, respec-
tively, against intra-abdominal infections caused by this patho-
gen. Results in patients with obstetric/gynecological infections
caused by E. faecalis were as good or better, despite the use of
a relatively low meropenem dosage (0.5 g, 8-hourly), such that
the satisfactory clinical response and pathogen eradication rates
against E. faecalis across all infections were at least 88%.
It is well established that carbapenems are highly active
against the major bacterial pathogens responsible for meningitis
[5,43,44]. However, imipenem/cilastatin is not indicated for
the treatment of such infections because of its propensity to
cause seizures [45,46]. In contrast, meropenem is well tolerated
by the central nervous system, even in patients with meningitis
treated with dosages of 6 g/day [47]. In the present analysis, the
overall rates of clinical success and pathogen eradication for
meropenem among meningitis patients were highly favourable,
often approaching 100%.
The efficacy of meropenem against pneumococcal men-
ingitis is particularly promising in view of the global spread of
penicillin resistance in S. pneumoniae [48,49]. Decreased peni-
cillin susceptibility among S. pneumoniae (often associated with
reduced susceptiblity to non-b-lactam antibacterials) has been
associated with meningitis treatment failure with third-gen-
eration cephalosporins [50]. Although meropenem MICs
against penicillin-resistant S. pneumoniae are increased compared
with penicillin-sensitive strains, they remain 1 mg/L [5,6,51].
In clinical studies, meropenem has proved as effective and well
tolerated as cefotaxime and ceftriaxone as empirical mon-
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otherapy in adults and children with meningitis [34–36],
although clinical experience in patients with infections caused
by penicillin-resistant S. pneumoniae is limited. In areas where
penicillin resistance is highly prevalent, the addition of van-
comycin to meropenem to ensure adequate antipneumococcal
activity is feasible and supported by evidence of synergy, both
in vitro and in vivo, between these agents [52]. Thus, meropenem
monotherapy is likely to emerge as a highly effective alternative
to existing agents for the treatment of patients with bacterial
meningitis.
The widespread use of many antibacterials can lead to
increasing problems of resistance. In the case of meropenem,
however, preliminary evidence from a multinational sus-
ceptibility surveillance study (MYSTIC: Meropenem Yearly
Susceptibility Test Information Collection) suggests that exten-
sive use of this agent has not been associated with an increase
in MIC values [53]. These data give encouragement that mer-
openem MICs will remain low and consistent with sustained
clinical efficacy against infections caused by single or multiple
bacterial pathogens.
In summary, the in vitro profile of meropenem, characterized
by a potent ultra-broad spectrum of activity, b-lactamase stab-
ility, and a low likelihood for the development of resistance,
translates into good clinical efficacy.
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